Hong B - Search Results

1

The CDK1/TFCP2L1/ID2 cascade offers a novel combination therapy strategy in a preclinical model of bladder cancer.

Heo J, Lee J, Nam YJ, Kim Y, Yun H, Lee S, Ju H, Ryu CM, Jeong SM, Lee J, Lim J, Cho YM, Jeong EM, Hong B, Son J, Shin DM. Heo J, et al. Among authors: hong b. Exp Mol Med. 2022 Jun;54(6):801-811. doi: 10.1038/s12276-022-00786-0. Epub 2022 Jun 21. Exp Mol Med. 2022. PMID: 35729325 Free PMC article.

2

Value of immediate second resection of the tumor bed to improve the effectiveness of transurethral resection of bladder tumor.

Kim W, Song C, Park S, Kim J, Park J, Kim SC, Cho YM, Hong B, Ahn H. Kim W, et al. Among authors: hong b. J Endourol. 2012 Aug;26(8):1059-64. doi: 10.1089/end.2011.0576. Epub 2012 Apr 30. J Endourol. 2012. PMID: 22390720 Clinical Trial.

3

Clinicopathological features of Xp11.2 translocation renal cell carcinoma.

Lim B, You D, Jeong IG, Kwon T, Hong S, Song C, Cho YM, Hong B, Hong JH, Ahn H, Kim CS. Lim B, et al. Among authors: hong jh, hong s, hong b. Korean J Urol. 2015 Mar;56(3):212-7. doi: 10.4111/kju.2015.56.3.212. Epub 2015 Feb 26. Korean J Urol. 2015. PMID: 25763125 Free PMC article.

4

Lymph node density vs. the American Joint Committee on Cancer TNM nodal staging system in node-positive bladder cancer in patients undergoing extended or super-extended pelvic lymphadenectomy.

Lee D, Yoo S, You D, Hong B, Cho YM, Hong JH, Kim CS, Ahn H, Ro JY, Jeong IG. Lee D, et al. Among authors: hong jh, hong b. Urol Oncol. 2017 Apr;35(4):151.e1-151.e7. doi: 10.1016/j.urolonc.2016.06.021. Epub 2017 Jan 27. Urol Oncol. 2017. PMID: 28139370

5

Phosphorylation of TFCP2L1 by CDK1 is required for stem cell pluripotency and bladder carcinogenesis.

Heo J, Noh BJ, Lee S, Lee HY, Kim Y, Lim J, Ju H, Yu HY, Ryu CM, Lee PC, Jeong H, Oh Y, Kim K, Kim SY, Son J, Hong B, Kim JS, Cho YM, Shin DM. Heo J, et al. Among authors: hong b. EMBO Mol Med. 2020 Jan 9;12(1):e10880. doi: 10.15252/emmm.201910880. Epub 2019 Nov 11. EMBO Mol Med. 2020. PMID: 31709755 Free PMC article.

6

Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.

Lee Y, Kim YS, Hong B, Cho YM, Lee JL. Lee Y, et al. Among authors: hong b. J Cancer Res Clin Oncol. 2021 Nov;147(11):3421-3429. doi: 10.1007/s00432-021-03582-x. Epub 2021 Mar 14. J Cancer Res Clin Oncol. 2021. PMID: 33715088

7

Glutathione dynamics is a potential predictive and therapeutic trait for neoadjuvant chemotherapy response in bladder cancer.

Kim Y, Ju H, Yoo SY, Jeong J, Heo J, Lee S, Park JM, Yoon SY, Jeong SU, Lee J, Yun H, Ryu CM, Lee J, Nam YJ, Kwon H, Son J, Jeong G, Oh JH, Sung CO, Jeong EM, An J, Won S, Hong B, Lee JL, Cho YM, Shin DM. Kim Y, et al. Among authors: hong b. Cell Rep Med. 2023 Oct 17;4(10):101224. doi: 10.1016/j.xcrm.2023.101224. Epub 2023 Oct 4. Cell Rep Med. 2023. PMID: 37797616 Free PMC article.

8

Invasiveness of Upper Tract Urothelial Carcinoma: Clinical Significance and Integrative Diagnostic Strategy.

Ahn B, Kim D, Park KJ, Park JM, Yoon SY, Hong B, Cho YM, Kim D. Ahn B, et al. Among authors: hong b. Cancer Res Treat. 2023 Dec 18. doi: 10.4143/crt.2023.1150. Online ahead of print. Cancer Res Treat. 2023. PMID: 38147818 Free article.

9

Effectiveness of Adjuvant Chemotherapy in Variant Histology Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Stabilized Inverse Probability Treatment Weighting Analysis of Single Center Experience.

Park I, Suh J, Lim B, Song C, You D, Jeong IG, Hong JH, Ahn H, Cho YM, Lee J, Hong B. Park I, et al. Among authors: hong jh, hong b. Clin Genitourin Cancer. 2024 Jun;22(3):102069. doi: 10.1016/j.clgc.2024.102069. Epub 2024 Mar 4. Clin Genitourin Cancer. 2024. PMID: 38580522

10

Risk factors for failing to complete gemcitabine-cisplatin neoadjuvant chemotherapy in muscle invasive bladder cancer patients.

Kang H, Suh J, You D, Jeong IG, Hong B, Hong JH, Ahn H, Lim B. Kang H, et al. Among authors: hong jh, hong b. Investig Clin Urol. 2024 May;65(3):256-262. doi: 10.4111/icu.20230389. Investig Clin Urol. 2024. PMID: 38714516 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,930 results

Search Page